|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Muhiphase Euler-Lagrange CFD simulation applied to Wet Flue Gas Desulphurisation technology 显示文摘 | Marocco L Inzoli F | 2009 | International Journal of Multiphase Flow2009，35，2： | 1 |
| 2 | Multiphase Euler - Lagrange CFD simulation applied to Wet Flue Gas Desulphu- risation technology显示文摘 | Marocco L Inzoli F | 2009 | International Journal of Multi- phase Flow2009，35，2： | 1 |
| 3 | Laparoendoscopic single-site surgery (LESS) for ovarian cyst enucleation:report of first 3 cases显示文摘 | Fagotti A Fanfani F Marocco F | 2009 | Fertil Steril2009，92，11： | 1 |
| 4 | Multiphase Euler-Lagrange CFD simulation applied to wet flue gas desulphurization technology International显示文摘 | MAROCCO L INZOLI F | | 0，，2： | 1 |
| 5 | Laparoendoscopic single- site surgery (LESS) for ovarian cyst enucleation : report of first 3 cases显示文摘 | Fagotti A Fanfani F Marocco F | 2009 | Fertil Steril2009，92，： | 1 |
| 6 | Multiphase Euler-Lagrange CFD simulation applied to wet flue gas desulphurisation technology显示文摘 | Marocco L Inzoli F | 2009 | International Journal of Multiphase Flow2009，35，2： | 1 |
| 7 | 显示文摘 | Maroccos R Vaz F Marinho A | 2001 | Ophthalmology2001，98，11： | 1 |
| 8 | Laparoendoscopic singlesite surgery for fertility-sparing staging of border line ovarian tumors: initial experience 显示文摘 | Marocco F Fanfani F Rossitto C | 2010 | Surg Laparosc Endose Percutan Tech2010，20，： | 1 |
| 9 | Multiphase Euler-Lagrange CFD simulation applied to wet flue gas desulphurization technology显示文摘 | MAROCCO L INZOLI F | 2009 | International Journal of Multiphase Flow2009，35，2： | 1 |
| 10 | Multiphase Euler-lagrange CFD Simulation Applied to Wet Flue Gas Desulphurisation Technology显示文摘 | Marocco L Inzoli F | 2009 | Multiphase Flow2009，35，： | 1 |
| 11 | Flue Gas Desulfurization in an Internally Circulating Fluidized Bed Reactor显示文摘 | Marocco L Inzoli F | 2005 | Powder Technology2005，154，： | 1 |
| 12 | Lapareendoscopic singlesite surgery ( LESS ) for ovarian cyst enucleation:report of first 3cases 显示文摘 | Fagotti A Fanfani F Marocco F | 2009 | FertilSteril2009，92，3： | 1 |
| 13 | 查看详情显示文摘 | Marocco F Smart R L Jones H R A | | 0，，： | 1 |
| 14 | 治疗前血清血红蛋白水平作为预测局部晚期宫颈鳞癌对新辅助化疗的反应指标的初步报道显示文摘The aim of this study was to evaluate the predictive value of pretreatment serum hemoglobin level (Hb) together with a series of clinical and pathological variables available before neoadjuvant chemotherapy in locally advanced squamous cervical cancer. Methods. The influence on response to neoadjuvant chemotherapy of a series of pretreatment clinico-pathological features: hemoglobin level at diagnosis, age, parity, menopausal status, body mass index, clinical stage, tumor diameter, and nuclear grading were analyzed on 73 patients with locally advanced cervical cancer treated with platinum-based neoadjuvant chemotherapy followed by radical surgery. The relationships between pretreatment variables and response to chemotherapy were assessed in univariate and multivariate settings. Aunivariate and multivariate logistic regression model was adapted to predict an “ optimal” response (pathological complete response or more than 50% reduction in tumoral diameter) or “ sub-optimal” response ( < 50% reduction in tumoral diameter). Results. Seventy-three patients-clinical stage: Ib2: 29 (39.7% ) Ⅱ a: 22 (30.1% ) Ⅱ b: 22 (30.1% )-received 3 cycles of platinum-based neoadjuvant chemotherapy followed by type Ⅲ radical hysterectomy. A complete response to neoadjuvant chemotherapy was significantly associated with higher level of pretreatment hemoglobin (mean 14.0 mg/dl) compared to patients with ≥ 50% response (12.7 mg/dl) or < 50% (11.9 mg/dl) (P = 0.002). At multivariate analysis, Hb level was found to be the most powerful and significantly related factor to response to neoadjuvant chemotherapy. A hemoglobin threshold of 12 mg/dl was able to distinguish between patientswith ≥ 12 mg/dl-at higher probability to respond to neoadjuvant chemotherapy from the ones at lower probability (hemoglobin level under 12 mg/dl). Patients with a complete response to chemotherapy had a 100% survival compared to 93.1% and 53.8% for patients with responses ≥ 50% and < 50% respectively (P = 0.0001). Patients with a pretreatment hemoglobin level of ≥ 12 mg/dl showed a survival of 87% compared to 63% for patients with a lower hemoglobin level (P = 0.008). Conclusions. Pretreatment Hb level showed a prognostic and independent predictive value for response to neoadjuvant chemotherapy in locally advanced cervical cancer. In our preliminary report, performed on a limited sample, a threshold of 12 mg/dl seems to be helpful to distinguish between “ optimal” and “ non-optimal” response. | Fuso L Mazzola S Marocco F 柳蕴 | 2006 | 世界核心医学期刊文摘(妇产科学分册)2006，0，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员